pharmacokinetic profiling<\/a> of oligo-based therapeutics.<\/p>\n\n\n\nBy identifying the conditions under which oligos remain stable or are degraded in the bloodstream, researchers can design more effective and durable therapies. This allows them to optimize dosing regimens and improve the success rate of preclinical and clinical evaluations of new drug candidates.<\/p>\n\n\n\n
Comparisons with prior research highlight this study\u2019s significance, particularly in its systematic evaluation of anticoagulants and handling conditions. This approach addresses gaps in existing methodologies, offering a more flexible framework for oligo stability assessment. Continued exploration into these drugs is crucial, focusing on understanding the interaction between oligos and alternative biological matrices. Further research could aim to elucidate the mechanisms of degradation in different environments and develop enhanced stabilization strategies to extend the half-life and efficacy of oligo-based therapeutics.<\/p>\n\n\n\n
The implications of these results are far-reaching for oligos\u2019 pharmacokinetics and metabolism profiles. By providing a clearer understanding of how these molecules behave in plasma, the study helps optimize oligo designs for improved stability, efficacy, and safety. This ultimately enhances drug development and therapeutic outcomes for these molecules.<\/p>\n\n\n\n
Future work could explore its use in personalized medicine, predicting patient-specific responses based on plasma stability profiles and guiding dosage and treatment regimens for oligonucleotide therapeutics.<\/p>\n\n\n\n
A final word<\/h2>\n\n\n\n The study successfully developed a reliable in vitro<\/em> plasma stability assay for oligonucleotides, highlighting the importance of anticoagulant usage, plasma\/serum choice, and plasma handling in assessing oligo stability. It also demonstrated that Heparin is a more suitable anticoagulant and that freezing treatments do not significantly impact enzymatic activity. It is recommended that this plasma stability assay be integrated into the early stages of drug development to guide the selection and optimization of oligo candidates. This assay can significantly contribute to designing oligo-based drugs efficiently and with improved pharmacokinetic profiles, supporting the advancement of safe and effective therapeutics.<\/p>\n\n\n\n<\/p>\n\n\n\n
\n\n\n\n<\/p>\n\n\n\n
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec\u2019s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need \u2013 and to realize the vision that “every drug can be made, and every disease can be treated.”<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"Oligonucleotides (oligos), including small interference RNAs (siRNAs) and antisense oligonucleotides (ASOs), represent a novel class of therapeutic agents capable of precisely targeting and regulating gene expression. This precision allows the potential treatment of various diseases, from genetic disorders to cancers, by silencing harmful genes or correcting genetic abnormalities. <\/p>\n","protected":false},"author":16,"featured_media":7666,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","content-type":"","footnotes":""},"categories":[8,40,11],"tags":[37],"yoast_head":"\n
A Step Forward in Oligo Therapy: A New Assay for Testing Oligo Stability in Plasma<\/title>\n \n \n \n \n \n \n \n \n \n \n \n \n\t \n\t \n\t \n \n \n \n\t \n\t \n\t \n